2022
DOI: 10.1016/j.ebiom.2022.104270
|View full text |Cite
|
Sign up to set email alerts
|

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
72
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 105 publications
(77 citation statements)
references
References 43 publications
3
72
2
Order By: Relevance
“…An increase in pathogenicity of BA.5 over BA.1 in K18-hACE2 mice may be associated with an increased reliance on TMPRSS2 106 . The early omicron variants tended to be less dependent on TMPRSS2 than original ancestral isolates, and showed an increased propensity to use the endocytic route of entry; a shift associated with lower pathogenicity and changes in spike 107,108 .…”
Section: Discussionmentioning
confidence: 99%
“…An increase in pathogenicity of BA.5 over BA.1 in K18-hACE2 mice may be associated with an increased reliance on TMPRSS2 106 . The early omicron variants tended to be less dependent on TMPRSS2 than original ancestral isolates, and showed an increased propensity to use the endocytic route of entry; a shift associated with lower pathogenicity and changes in spike 107,108 .…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, BA.4 and BA.5 cause a new wave of infection due to their capability of neutralizing previous antibodies [ 29 ]. BA.5, having greater sensitivity to TMPRSS2 inhibitors, increases the transmission and severity of the disease [ 30 ]. In India, the BA.4 and BA.5 variants were less severe, with less than 1% availability.…”
Section: Omicron Subvariantsmentioning
confidence: 99%
“…It soon became apparent from various studies that the ability of the AZD7442 combination to neutralize the Omicron variants was diminished. In one of the first reports, Aggarwal et al showed that cilgavimab had completely lost its effectiveness against B.1.1529, while tixagevimab had a 73.8-fold reduction compared to the A.2.2 ancestral strain [ 82 ]. Zhou et al reported a 359-fold activity decrease against BA.1 and 1920-fold against BA.2 compared to the D614G ancestral virus [ 83 ].…”
Section: Management Of Covid-19 In Pwhmentioning
confidence: 99%